Cold virus turned cancer killer: new trial launches

NCT ID NCT06977737

Recruiting now Disease control Sponsor: Accession Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Dec 16, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This early-phase trial tests a new drug called ATTR-01 in adults with certain solid tumors that have not responded to standard treatments. ATTR-01 is a modified cold virus designed to infect and multiply only in cancer cells, delivering an immune-boosting therapy to help the body fight the tumor. The study aims to find the safest and most effective dose and to see if it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

, St James' University Hospital
RECRUITING

Leeds, United Kingdom
Beatson West of Scotland Cancer Centre
RECRUITING

Glasgow, Scotland, United Kingdom
Churchill Hospital
RECRUITING

Oxford, United Kingdom
General Hospital San Pedro - START
NOT_YET_RECRUITING

Rioja, Spain
START Barcelona
RECRUITING

Barcelona, Spain
Start Fjd
RECRUITING

Madrid, Spain
Start Hm Ciocc
RECRUITING

Madrid, Spain
Velindre Cancer Centre
RECRUITING

Cardiff, Wales, United Kingdom

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR, ADULT